MMRV two-dose regimen safe: study

In Australia, MMRV is only funded for children at 18 months after a first dose of MMR at 12 months because it is associated with an increased risk of fever and febrile convulsions when given as a first dose in children 12 months and younger.

In the current study, funded by ProQuad sponsor Merck, researchers reviewed safety data from five multicentre trials involving 2780 children who received their first MMRV dose at 12 months and a second dose in the following 3—6 months.

Overall, a vaccine-related systemic adverse event was reported by 31.7% of children following the first dose and 14.6% of children